Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT

被引：30

作者：

Lee, Jungwhoi ^{[1
]}

Ku, Taeyun ^{[1
,2
]}

Yu, Hana ^{[1
]}

Chong, Kyuha ^{[1
,2
]}

Ryu, Seung-Wook ^{[1
,3
]}

Choi, Kyungsun ^{[1
,3
]}

Choi, Chulhee ^{[1
,2
,3
]}

机构：

[1] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Cell Signaling & Bio Imaging Lab, Taejon 305701, South Korea

[2] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Taejon 305701, South Korea

[3] Korea Adv Inst Sci & Technol, Inst BioCentury, Taejon 305701, South Korea

来源：

CANCER LETTERS | 2012年 / 318卷 / 02期

基金：

新加坡国家研究基金会;

关键词：

VEGF; FAK; AKT; Apoptosis; Autocrine signaling; ANGIOGENESIS; CANCER; DISEASES; KINASE; CELLS;

D O I：

10.1016/j.canlet.2011.12.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Blockade of VEGF signaling using RNA interferences, a neutralizing antibody, an antagonizing soluble VEGF receptor, and a receptor tyrosine kinase inhibitor induced anti-tumor effects in human astrocytoma U251-MG and fibrosarcoma HT-1080 in vitro in a dose-dependent manner. Furthermore, blockade of VEGF-A using the doxycycline-inducible VEGF-A RNA interference system showed a significant antitumor effect in a murine HT-1080-xenograft model. Anti-tumor effect through the blockade of VEGF signaling was mediated by FAK and AKT pathway in vitro and in vivo. These results collectively indicate that VEGF-A and its receptors can act as key inducer of tumor growth as well as angiogenesis. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：221 / 225

页数：5

共 14 条

[1] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[2] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[3] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[4] Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J].

Carmeliet, Peter ;

Jain, Rakesh K. .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :417-427

[5] Adverse effects of anticancer agents that target the VEGF pathway [J].

Chen, Helen X. ;

Cleck, Jessica N. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (08) :465-477

[6] Blockade of vascular endothelial growth factor sensitizes tumor-associated vasculatures to angiolytic therapy with a high-frequency ultrashort pulsed laser [J].

Choi, Hyosook ;

Choi, Myunghwan ;

Choi, Kyungsun ;

Choi, Chulhee .

MICROVASCULAR RESEARCH, 2011, 82 (02) :141-146

[7] Dynamic fluorescence imaging for multiparametric measurement of tumor vasculature [J].

Choi, Myunghwan ;

Choi, Kyungsun ;

Ryu, Seung-Wook ;

Lee, Jungwhoi ;

Choi, Chulhee .

JOURNAL OF BIOMEDICAL OPTICS, 2011, 16 (04)

[8] PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].

FERRARA, N ;

HENZEL, WJ .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858

[9] Clinical applications of angiogenic growth factors and their inhibitors [J].

Ferrara, N ;

Alitalo, K .

NATURE MEDICINE, 1999, 5 (12) :1359-1364

[10]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

← 1 2 →